Vaccination with recombinant L7/L12-Truncated Omp31 protein induces Th1 responce and protection against Brucella infection in BALB/c mice
5th Asia Pacific Global Summit and Expo on Vaccines & Vaccination
July 27-29, 2015 Brisbane, Australia

Maryam Golshani, Sima Rafati, Seyed Davar Siadat, Mehdi Nejati-Mohimani, fereshteh Shahcheraghi and Saeid Bouzari

Posters-Accepted Abstracts: J Vaccines Vaccin

Abstract:

Background: Brucellosis is the most common bacterial zoonotic disease worldwide and,at present, no human vaccine is available for the prevention of brucellosis. Brucella melitensis and Brucella abortus are the most common causes of human brucellosis. The Outer membrane protein 31 (Omp31) and L7/L12 are immunodominant and protective antigens conserved in human Brucella pathogens. Materials and Methods: In the current study, we evaluated the humoral and cellular immune responses induced by a fusion protein designed in silico based on the truncated form of Omp31 (TOmp31) and L7-L12 antigens and expressed in vitro in a prokaryotic host. Results: Vaccination of BALB/c mice with the rL7/L12-TOmp31 provided the significant protection level against B. melitenisis and B. abortus challenge. Moreover, rL7/L12-TOmp31 elicited a strong specific IgG response (higher IgG2a titers) and induced T cell proliferation marked with IFN-? and IL-2 production. Conclusion: The rL7/L12-TOmp31 could be a new potential antigen candidate for the development of a subunit vaccine against B. melitensis and B. abortus.